← Back to list
[New York] Updates to Carelon Medical Benefits Management, Inc. Clinical Appropriateness Guidelines
Act
by Nov 15, 2026
Effective date
Nov 15, 2026
Identified
Aug 12, 2026
Summary
Carelon Medical Benefits Management has updated clinical appropriateness guidelines effective November 15, 2026, with significant changes to vascular procedures, genetic/molecular testing criteria, and cancer treatment indications. Key changes include expanded indications for varicose vein treatments, new drug eligibility for cancer molecular testing (imlunestrant, niraparib, talazoparib), broader genetic testing requirements across multiple cancer types, and removal of certain age/stage restrictions. Billing teams must review each clinical area for prior authorization and medical necessity documentation changes.
Get alerts when payers change rules like this one
We check Anthem BCBS and other payers every day and email you when a change matches your specialty and state.
Get Anthem BCBS alertsPolicy Monitoring is free. No card required.
What to do
by Nov 15, 2026 · 9 steps
01Billing team and clinical staff must implement the following changes in Anthem/Carelon authorization system and documentation templates.
02Vascular procedures - Update prior auth criteria for inframalleolar angioplasty (critical limb ischemia), thermal/non-thermal ablation of varicose veins, cyanoacrylate ablation for perforators, and genicular artery embolization (now requires case-by-case review, not automatically approved).
03Genetic/Molecular Testing - Modify authorization rules to require all test components demonstrate clinical utility; add imlunestrant, niraparib, and talazoparib as eligible triggers for ESR1/BRCA/HRD testing; expand breast cancer molecular testing to stages IIB, IIIA, IIIB, IIIC (previously metastatic only); remove stage restrictions for pancreatic cancer testing; broaden prostate cancer testing to all metastatic indications (not just mCSPC).
04PFO Closure - Establish age cutoff at 60 years (not medically necessary if older); require RoPE score documentation.
05Vascular Embolization - Update indications for liver malignancy (add DEB-TACE, add drug-eluting bead criteria), portal vein embolization (now includes primary tumors), varicocele treatment, and complex congenital heart disease collaterals.
06Cancer Genetic Testing - Deny ctHPV DNA for oropharyngeal carcinoma recurrence; expand tissue-agnostic testing to include HER2; update comprehensive molecular panels for biliary, bladder, thyroid, and unknown primary cancers.
07Providers must update clinical documentation templates to capture new eligibility criteria.
08Deny claims for: WES/WGS/WTA testing; genicular artery embolization without medical justification; PFO closure in patients >60 years; breast cancer recurrence molecular testing; NIFTP somatic testing; isolated labial/lower extremity varicose veins without pelvic symptoms.
09Update denial templates and appeal guidelines before effective date to avoid processing delays.
Original notice
[New York] Updates to Carelon Medical Benefits Management, Inc. Clinical Appropriateness Guidelines
providernews.anthem.com · Always check the source before changing claims.
Related changes
See all Anthem BCBS changes →[New York] Updates to Carelon Medical Benefits Management Clinical Appropriateness GuidelinesHighEffective Nov 15, 2026 · Provider Bulletin[Ohio] Updates to Carelon Medical Benefits Management, Inc. Clinical Appropriateness GuidelinesHighEffective Nov 15, 2026 · Provider Bulletin[Georgia] Updates to Carelon Medical Benefits Management, Inc. Clinical Appropriateness GuidelinesHighEffective Nov 15, 2026 · Provider Bulletin[Virginia] Updates to Carelon Medical Benefits Management Clinical Appropriateness GuidelinesMediumEffective Nov 15, 2026 · Provider BulletinBrowse every Anthem BCBS change in the policy list